BridgeBio Oncology Therapeutics, Inc.
BBOTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, BridgeBio Oncology Therapeutics, Inc. focuses on Biotechnology services and products. BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and. The company carries a $708.1M market cap, placing it firmly in the small-cap category. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models.
Market Cap
$708.1M
Beta
0.22
P/E (TTM)
—
P/E (Fwd)
-4.13
EPS (TTM)
$-1.99
EPS (Fwd)
$-2.14
ROE
-62.2%
ROA
-37.2%
Cash
$252.3M
Total Debt
$2.6M
Free CF
-$86.1M
52W Change
-17.8%
Annual Financials
Cash vs Debt
BridgeBio Oncology Therapeutics, Inc. holds $252.3M in cash against $2.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$86.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -62.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, BridgeBio Oncology Therapeutics, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BridgeBio Oncology Therapeutics, Inc. and its sector.